Search - tctmd.com

Displaying 181 - 200 of 403

Sort: Relevancy | Date

SYNTAX Score Predicts Long-term Benefits of Left Main PCI and CABG: MAIN-COMPARE

News Daily News

SYNTAX Score Predicts Long-term Benefits of Left Main PCI and CABG: MAIN-COMPARE

Michael O'Riordan

February 03, 2020

Coronary Artery Targets Matter in Bilateral ITA CABG

News Daily News

Coronary Artery Targets Matter in Bilateral ITA CABG

Yael L. Maxwell

January 23, 2020

News Daily News

No Fewer MACE With Ticagrelor vs Clopidogrel in ACS Patients After PCI: Registry

January 15, 2020

EACTS Pulls Out of Left Main Guidelines After BBC Bombshell Alleging EXCEL Trial Cover-up

News Daily News

EACTS Pulls Out of Left Main Guidelines After BBC Bombshell Alleging EXCEL Trial Cover-up

Michael O'Riordan

December 10, 2019

ISCHEMIA Questions? Some Answers From David Maron

News Opinion Editor's Corner

ISCHEMIA Questions? Some Answers From David Maron

December 09, 2019

Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too

News Features

Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too

Michael O'Riordan

December 09, 2019

Uninformed Consent? Most Patients Misunderstand True Benefits of PCI

News Daily News

Uninformed Consent? Most Patients Misunderstand True Benefits of PCI

Michael O'Riordan

November 29, 2019

Complete Revascularization Benefits May Be Due to Stenting Vulnerable Plaques

News Conference News AHA 2019

Complete Revascularization Benefits May Be Due to Stenting Vulnerable Plaques

November 21, 2019

Aspirin Discontinuation Safe, Effective Strategy in ACS Subset: TWILIGHT

News Conference News AHA 2019

Aspirin Discontinuation Safe, Effective Strategy in ACS Subset: TWILIGHT

Yael L. Maxwell

November 17, 2019

DAPT Cuts Saphenous Vein Graft Failure After CABG: Meta-analysis

News Daily News

DAPT Cuts Saphenous Vein Graft Failure After CABG: Meta-analysis

Michael O'Riordan

October 17, 2019

FORZA: For Intermediate Lesions, OCT-Guided PCI Costs More, Yields Better Outcomes vs FFR

News Conference News TCT 2019

FORZA: For Intermediate Lesions, OCT-Guided PCI Costs More, Yields Better Outcomes vs FFR

October 01, 2019

TCTMD’s Top 10 Most Popular Stories for September 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2019

October 01, 2019

Off Script: A (Not So) Brief History of Aspirin’s Rise and Fall

News Opinion Off Script TCT 2019

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

September 29, 2019

Session III: DES - STOPDAPT, SMART-CHOICE, and TWILIGHT: Will These Trials Change Your Clinical Practice?

Presentation TCT 2019

STOPDAPT, SMART-CHOICE, and TWILIGHT: Will These Trials Change Your Clinical Practice?

Presenter: Aditya Kapoor

September 28, 2019

News Conference News TCT 2019

EXCEL at 5 Years: PCI for Left Main CAD Still Noninferior to CABG

Marcus A. Banks

September 28, 2019

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

News Conference News TCT 2019

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

September 19, 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

News Conference News ESC 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

September 03, 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

News Conference News ESC 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

September 02, 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

News Conference News ESC 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Michael O'Riordan

September 01, 2019

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Michael O'Riordan

August 22, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.